Evidence map›Paper›PMID 24166483›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2014

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.

Nicola Borthwick, Tina Ahmed, Beatrice Ondondo, Peter Hayes, Annie Rose, Umar Ebrahimsa, Emma-Jo Hayton, Antony Black, Anne Bridgeman, Maximillian Rosario and 11 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 200 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.Molecular therapy : the journal of the American Society of Gene Therapy · 2016
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Article
  20. Article

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 3 countries.

Nicola BorthwickThe Jenner Institute Laboratories, University of Oxford, Old Road Campus Research Building, Oxford, UK; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford, UK.
Tina AhmedThe Jenner Institute Laboratories, University of Oxford, Old Road Campus Research Building, Oxford, UK; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford, UK.
Beatrice OndondoThe Jenner Institute Laboratories, University of Oxford, Old Road Campus Research Building, Oxford, UK.
Peter HayesIAVI Human Immunology Laboratory, Imperial College, London, UK.
Annie RoseCentre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK.
Umar EbrahimsaCentre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK.
Emma-Jo HaytonCentre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK.
Antony BlackCentre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK; Current address: Institut Pasteur du Laos, Vientiane, Laos People's Democratic Republic.
Anne BridgemanThe Jenner Institute Laboratories, University of Oxford, Old Road Campus Research Building, Oxford, UK; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford, UK.
Maximillian RosarioMRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford, UK; Current address: Medical Microbiology and Immunology, Li Ka Shing Institute of Virology, 6-096 Katz Centre for Health Research, Edmonton, Alberta, Canada.
Adrian Vs HillThe Jenner Institute Laboratories, University of Oxford, Old Road Campus Research Building, Oxford, UK; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK; Clinical Biomanufacturing Facility, University of Oxford, Churchill Hospital, Oxford, UK.
Eleanor BerrieClinical Biomanufacturing Facility, University of Oxford, Churchill Hospital, Oxford, UK.
Sarah MoyleClinical Biomanufacturing Facility, University of Oxford, Churchill Hospital, Oxford, UK.
Nicole FrahmVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Josephine CoxIAVI Human Immunology Laboratory, Imperial College, London, UK.
Stefano CollocaOkairos, Rome, Italy.
Alfredo NicosiaOkairos, Rome, Italy; CEINGE, Naples, Italy; Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Jill GilmourIAVI Human Immunology Laboratory, Imperial College, London, UK.
Andrew J McMichaelMRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford, UK.
Lucy DorrellMRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford, UK.
Tomáš HankeThe Jenner Institute Laboratories, University of Oxford, Old Road Campus Research Building, Oxford, UK; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford, UK; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK; Clinical Biomanufacturing Facility, University of Oxford, Churchill Hospital, Oxford, UK. Electronic address: tomas.hanke@ndm.ox.ac.uk.
University of Oxford · GBJenner Institute · GBImperial College London · GBChurchill Hospital · GBFred Hutch Cancer Center · USUniversity of Naples Federico II · IT

Funding

Medical Research Council G0502048Medical Research Council G0701669Medical Research Council G1001757Medical Research Council MC_U137884179Wellcome Trust 090532Wellcome Trust 095540
6 · The paper itself

Abstract

Virus diversity and escape from immune responses are the biggest challenges to the development of an effective vaccine against HIV-1. We hypothesized that T-cell vaccines targeting the most conserved regions of the HIV-1 proteome, which are common to most variants and bear fitness costs when mutated, will generate effectors that efficiently recognize and kill virus-infected cells early enough after transmission to potentially impact on HIV-1 replication and will do so more efficiently than whole protein-based T-cell vaccines. Here, we describe the first-ever administration of conserved immunogen vaccines vectored using prime-boost regimens of DNA, simian adenovirus and modified vaccinia virus Ankara to uninfected UK volunteers. The vaccine induced high levels of effector T cells that recognized virus-infected autologous CD4(+) cells and inhibited HIV-1 replication by up to 5.79 log10. The virus inhibition was mediated by both Gag- and Pol- specific effector CD8(+) T cells targeting epitopes that are typically subdominant in natural infection. These results provide proof of concept for using a vaccine to target T cells at conserved epitopes, showing that these T cells can control HIV-1 replication in vitro.

Indexed as

AdolescentAdultAIDS VaccinesAmino Acid SequenceCells, CulturedConserved SequenceEpitope MappingEpitopes, T-LymphocyteFemalegag Gene Products, Human Immunodeficiency VirusHIV-1HIV InfectionsHumansMaleMiddle AgedMolecular Sequence DataAIDS VaccinesEpitopes, T-Lymphocytegag Gene Products, Human Immunodeficiency Viruspol Gene Products, Human Immunodeficiency VirusVaccines, DNA

Identifiers

PMID24166483
PMCPMC3911893
OpenAlexW1991737813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.